Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin and hypospadia

This article was originally published in The Tan Sheet

Executive Summary

FDA review of possible link between loratadine and birth defects "unlikely" to impact its decision on Schering-Plough's NDAs to switch Claritin OTC, agency says, noting many non-Rx products carry labeling restrictions concerning use during pregnancy. In addition to internal review being conducted by Division of Pulmonary & Allergy Drug Products and Office of Drug Safety, agency is consulting with outside experts in review of Swedish data, other information. FDA analysis, which extends to data for Rx Clarinex (desloratadine), could be completed by late September. Separate review by European Agency for the Evaluation of Medicinal Products is ongoing (1"The Tan Sheet" May 6, 2002, p. 3)...

You may also be interested in...

FDA Claritin Hypospadia Review Targeted For Summer Completion

FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months

Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process

CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.

Faulty CDC COVID-19 Assays Leave Only 12 US Jurisdictions With Testing Ability, CDC Director Says

Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts